Supernus Pharmaceuticals (SUPN) Short Interest Ratio & Short Volume → Missed NVDA? Buy this AI stock NOW (From Chaikin Analytics) (Ad) Free SUPN Stock Alerts $30.42 -0.41 (-1.33%) (As of 05/6/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Supernus Pharmaceuticals Short Interest DataCurrent Short Volume4,680,000 sharesPrevious Short Volume4,820,000 sharesChange Vs. Previous Month-2.90%Dollar Volume Sold Short$140.35 millionShort Interest Ratio / Days to Cover12.1Last Record DateApril 15, 2024Outstanding Shares54,970,000 sharesFloat Size52,390,000 sharesShort Percent of Float8.93%Today's Trading Volume335,111 sharesAverage Trading Volume376,066 sharesToday's Volume Vs. Average89% Short Selling Supernus Pharmaceuticals ? Sign up to receive the latest short interest report for Supernus Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatSUPN Short Interest Over TimeSUPN Days to Cover Over TimeSUPN Percentage of Float Shorted Over Time Ad Stansberry ResearchGlobal crypto currency reset (41 major banks signed up)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project... Here's everything you need to know. Supernus Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/20244,680,000 shares $140.35 million -2.9%8.9%12.1 $29.99 3/31/20244,820,000 shares $164.41 million -2.0%9.2%12.3 $34.11 3/15/20244,920,000 shares $162.26 million +11.6%9.4%13 $32.98 2/29/20244,410,000 shares $130.98 million +9.4%8.4%12.2 $29.70 2/15/20244,030,000 shares $115.50 million +7.8%7.7%12.1 $28.66 1/31/20243,740,000 shares $103.52 million -16.9%7.1%10.6 $27.68 Get the Latest News and Ratings for SUPN and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Supernus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 1/15/20244,500,000 shares $127.08 million +0.2%8.6%11.8 $28.24 12/31/20234,490,000 shares $129.94 million +0.9%N/A0 $28.94 12/15/20234,450,000 shares $121.26 million +7.0%8.5%10.9 $27.25 11/30/20234,160,000 shares $113.36 million +0.2%7.9%9.5 $27.25 11/15/20234,150,000 shares $118.65 million +4.5%7.9%9.3 $28.59 10/31/20233,970,000 shares $94.68 million +1.8%7.6%8.6 $23.85 10/15/20233,900,000 shares $96.88 million -0.5%7.5%8.6 $24.84 9/30/20233,920,000 shares $108.07 million -9.1%7.5%9.1 $27.57 9/15/20234,310,000 shares $125.98 million +3.9%8.2%9.6 $29.23 8/31/20234,150,000 shares $132.14 million +1.0%7.9%8.9 $31.84 8/15/20234,110,000 shares $130.86 million -1.0%7.9%8.8 $31.84 7/31/20234,150,000 shares $127.36 million -25.0%8.0%8.7 $30.69 7/15/20235,530,000 shares $166.07 million -0.9%10.6%12.5 $30.03 6/30/20235,580,000 shares $167.73 million +2.2%10.7%12.4 $30.06 6/15/20235,460,000 shares $183.40 million +3.2%10.5%12.5 $33.59 5/31/20235,290,000 shares $175.31 million +10.9%10.1%13.3 $33.14 5/15/20234,770,000 shares $165.71 million +6.5%9.1%11.6 $34.74 4/30/20234,480,000 shares $165.13 million +10.6%8.6%11.2 $36.86 4/15/20234,050,000 shares $146.04 million +1.5%7.8%9.7 $36.06 3/31/20233,990,000 shares $144.56 million -10.5%7.7%9.6 $36.23 3/15/20234,460,000 shares $158.37 million -3.5%8.6%10.4 $35.51 2/28/20234,620,000 shares $173.67 million -4.7%8.9%11.5 $37.59 2/15/20234,850,000 shares $187.02 million -9.4%9.4%12.7 $38.56 1/31/20235,350,000 shares $219.40 million -3.3%10.3%13.2 $41.01 1/15/20235,530,000 shares $220.54 million +0.6%10.7%15 $39.88 12/30/20225,500,000 shares $196.19 million +11.8%10.6%14.3 $35.67 12/15/20224,920,000 shares $174.56 million -13.4%9.5%12.6 $35.48 11/30/20225,680,000 shares $208.57 million -0.5%11.0%14.6 $36.72 11/15/20225,710,000 shares $194.14 million -3.4%11.0%14.6 $34.00 10/31/20225,910,000 shares $202.54 million -1.8%11.5%14.6 $34.27 10/15/20226,020,000 shares $195.41 million -1.3%11.7%14.5 $32.46 9/30/20226,100,000 shares $206.49 million -0.7%11.9%14.6 $33.85 9/15/20226,140,000 shares $213.86 million +8.1%12.0%16.1 $34.83 8/31/20225,680,000 shares $194.43 million +3.8%11.1%15.5 $34.23Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years (Ad)If you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)Watch my video for all of the details SUPN Short Interest - Frequently Asked Questions What is Supernus Pharmaceuticals' current short interest? Short interest is the volume of Supernus Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of April 15th, traders have sold 4,680,000 shares of SUPN short. 8.93% of Supernus Pharmaceuticals' shares are currently sold short. Learn More on Supernus Pharmaceuticals' current short interest. What is a good short interest ratio for Supernus Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. SUPN shares currently have a short interest ratio of 12.0. Learn More on Supernus Pharmaceuticals's short interest ratio. Which institutional investors are shorting Supernus Pharmaceuticals? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Supernus Pharmaceuticals: Concourse Financial Group Securities Inc., and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Supernus Pharmaceuticals? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 8.93% of Supernus Pharmaceuticals' floating shares are currently sold short. Is Supernus Pharmaceuticals' short interest increasing or decreasing? Supernus Pharmaceuticals saw a drop in short interest in April. As of April 15th, there was short interest totaling 4,680,000 shares, a drop of 2.9% from the previous total of 4,820,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Supernus Pharmaceuticals' float size? Supernus Pharmaceuticals currently has issued a total of 54,970,000 shares. Some of Supernus Pharmaceuticals' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Supernus Pharmaceuticals currently has a public float of 52,390,000 shares. How does Supernus Pharmaceuticals' short interest compare to its competitors? 8.93% of Supernus Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Supernus Pharmaceuticals: Pacira BioSciences, Inc. (7.42%), Innoviva, Inc. (18.46%), Corcept Therapeutics Incorporated (23.68%), Arcutis Biotherapeutics, Inc. (17.02%), Ocular Therapeutix, Inc. (9.47%), ORIC Pharmaceuticals, Inc. (13.97%), Phathom Pharmaceuticals, Inc. (43.45%), Karyopharm Therapeutics Inc. (20.23%), BioXcel Therapeutics, Inc. (5.64%), Perrigo Company plc (2.88%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.70 billion), Occidental Petroleum Co. ($3.52 billion), Charter Communications, Inc. ($3.14 billion), General Motors ($2.68 billion), Coinbase Global, Inc. ($2.57 billion), Moderna, Inc. ($2.18 billion), Tractor Supply ($2.10 billion), Royal Caribbean Cruises Ltd. ($1.91 billion), TC Energy Co. ($1.90 billion), and Williams-Sonoma, Inc. ($1.78 billion). View all of the most shorted stocks. What does it mean to sell short Supernus Pharmaceuticals stock? Short selling SUPN is an investing strategy that aims to generate trading profit from Supernus Pharmaceuticals as its price is falling. SUPN shares are trading down $0.41 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Supernus Pharmaceuticals? A short squeeze for Supernus Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of SUPN, which in turn drives the price of the stock up even further. How often is Supernus Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including SUPN, twice per month. The most recent reporting period available is April, 15 2024. More Short Interest Resources from MarketBeat Related Companies: PCRX Short Squeeze INVA Short Squeeze CORT Short Squeeze ARQT Short Squeeze OCUL Short Squeeze ORIC Short Squeeze PHAT Short Squeeze KPTI Short Squeeze BTAI Short Squeeze PRGO Short Squeeze Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:SUPN) was last updated on 5/6/2024 by MarketBeat.com Staff From Our PartnersThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldCould Your Accounts Be Frozen?Allegiance GoldAI “wealth window” is closing June 25thParadigm PressThe asset beating inflation by 4xColonial MetalsHe Is Giving Away BitcoinCrypto Swap ProfitsMissed NVDA? Buy this AI stock NOWChaikin AnalyticsElon to Transform U.S. Economy? Porter & CompanyRSVP: Charles Payne’s Cash Flow WorkshopUnstoppable Prosperity